ES2307653T3 - Preparaciones que contienen nateglinida. - Google Patents
Preparaciones que contienen nateglinida. Download PDFInfo
- Publication number
- ES2307653T3 ES2307653T3 ES01976817T ES01976817T ES2307653T3 ES 2307653 T3 ES2307653 T3 ES 2307653T3 ES 01976817 T ES01976817 T ES 01976817T ES 01976817 T ES01976817 T ES 01976817T ES 2307653 T3 ES2307653 T3 ES 2307653T3
- Authority
- ES
- Spain
- Prior art keywords
- nateglinide
- derivatives
- preparation containing
- amorphous
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 69
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 title description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims abstract description 148
- 229960000698 nateglinide Drugs 0.000 claims abstract description 148
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 229920003169 water-soluble polymer Polymers 0.000 claims description 22
- 239000013078 crystal Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 235000002639 sodium chloride Nutrition 0.000 claims description 12
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- -1 polyoxyethylene Polymers 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- 235000011083 sodium citrates Nutrition 0.000 claims description 8
- 239000001488 sodium phosphate Substances 0.000 claims description 8
- 235000011008 sodium phosphates Nutrition 0.000 claims description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 150000003841 chloride salts Chemical class 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 abstract description 4
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 32
- 238000004090 dissolution Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000004321 preservation Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009477 fluid bed granulation Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101100120289 Drosophila melanogaster Flo1 gene Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-324373 | 2000-10-24 | ||
| JP2000324373 | 2000-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2307653T3 true ES2307653T3 (es) | 2008-12-01 |
Family
ID=18801918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01976817T Expired - Lifetime ES2307653T3 (es) | 2000-10-24 | 2001-10-23 | Preparaciones que contienen nateglinida. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7605180B2 (ko) |
| EP (1) | EP1334720B1 (ko) |
| JP (3) | JP4501054B2 (ko) |
| KR (1) | KR100869039B1 (ko) |
| CN (1) | CN100352432C (ko) |
| AT (1) | ATE406885T1 (ko) |
| AU (1) | AU2001295999A1 (ko) |
| BR (1) | BR0114896A (ko) |
| CA (1) | CA2426263C (ko) |
| DE (1) | DE60135674D1 (ko) |
| DK (1) | DK1334720T3 (ko) |
| ES (1) | ES2307653T3 (ko) |
| MX (1) | MXPA03003685A (ko) |
| PT (1) | PT1334720E (ko) |
| RU (1) | RU2271805C2 (ko) |
| TW (1) | TWI283573B (ko) |
| WO (1) | WO2002034254A1 (ko) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1258249B1 (en) * | 1999-12-28 | 2005-11-23 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| BR0109336A (pt) * | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
| MXPA03003483A (es) * | 2000-10-18 | 2003-07-14 | Ajinomoto Kk | Procedimiento para la preparacion de acilfenilalaninas. |
| RU2273629C2 (ru) * | 2000-10-18 | 2006-04-10 | Адзиномото Ко., Инк. | Способы получения кристаллов натеглинида |
| DK1334964T3 (da) * | 2000-10-24 | 2007-09-24 | Ajinomoto Kk | Fremgangsmåde til fremstilling af nateglinidkrystaller med B form |
| MXPA03003686A (es) * | 2000-10-24 | 2004-01-26 | Ajinomoto Kk | Preparaciones hidrofilas de farmaco que contienen nateglinida. |
| ATE406885T1 (de) * | 2000-10-24 | 2008-09-15 | Ajinomoto Kk | Nateglinid enthaltende präparate |
| JP4833464B2 (ja) * | 2001-11-28 | 2011-12-07 | 大正製薬株式会社 | 難溶性薬物含有固形製剤の製造方法 |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| KR100882156B1 (ko) | 2003-08-08 | 2009-02-06 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| WO2005020979A1 (en) * | 2003-09-03 | 2005-03-10 | Ranbaxy Laboratories Limited | A process for the preparation of pharmaceutical compositions of nateglinide |
| US20070219250A1 (en) * | 2003-11-28 | 2007-09-20 | Romi Singh | Pharmaceutical Compositions of Nateglinide |
| WO2005094812A1 (ja) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
| KR20070040389A (ko) * | 2004-08-10 | 2007-04-16 | 아지노모토 가부시키가이샤 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
| EP1891971A4 (en) * | 2005-01-31 | 2010-02-03 | Ajinomoto Kk | MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA |
| DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
| JP4463875B2 (ja) | 2007-03-29 | 2010-05-19 | 第一三共株式会社 | 医薬組成物 |
| TR200801178A2 (tr) * | 2008-02-22 | 2009-09-23 | Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. | Nateglinid ve surfaktan-ph ayarlayıcı sistemi içeren oral tablet kompozisyonları |
| CN101590063A (zh) * | 2008-05-26 | 2009-12-02 | 中国科学院上海生命科学研究院 | 丹参酮iia在制备治疗肥胖及胰岛素抵抗的药物中的应用 |
| HUE031059T2 (en) | 2010-03-19 | 2017-06-28 | Daiichi Sankyo Co Ltd | Procedure for improving anticoagulant administration |
| WO2011157986A1 (en) | 2010-06-14 | 2011-12-22 | Cipla Limited | A process for the preparation of nateglinide |
| BR112014002397B1 (pt) | 2011-08-10 | 2021-08-03 | Daiichi Sankyo Company, Limited | Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida |
| CN102813636B (zh) * | 2012-08-28 | 2014-04-16 | 西南药业股份有限公司 | 那格列奈片及其制备方法 |
| CA2918570A1 (en) * | 2013-07-22 | 2015-01-29 | Sandoz Ag | Formulations containing amorphous dapagliflozin |
| JP6647902B2 (ja) * | 2015-10-30 | 2020-02-14 | 株式会社ファンケル | 徐放性顆粒剤 |
| KR20240025990A (ko) * | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
| FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| JPH0249720A (ja) * | 1988-05-18 | 1990-02-20 | Mitsubishi Kasei Corp | 難溶性薬剤組成物 |
| US5041232A (en) * | 1990-03-16 | 1991-08-20 | Lever Brothers Company, Division Of Conopco, Inc. | Sulfonimines as bleach catalysts |
| JPH0415221A (ja) | 1990-05-08 | 1992-01-20 | Daicel Chem Ind Ltd | ポリカーボネートの製造法 |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| JP2508949B2 (ja) * | 1991-07-30 | 1996-06-19 | 味の素株式会社 | Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法 |
| ES2364145T3 (es) | 1996-11-15 | 2011-08-25 | Ajinomoto Co., Inc. | Composición de nateglinida en comprimidos. |
| TW486370B (en) * | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| JP2002509103A (ja) * | 1998-01-20 | 2002-03-26 | アプライド・アナリティカル・インダストリーズ，インコーポレイテッド | 経口液体組成物 |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| EP1258249B1 (en) | 1999-12-28 | 2005-11-23 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| BR0109336A (pt) | 2000-03-17 | 2003-06-24 | Ajinomoto C0 Inc | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico |
| RU2273629C2 (ru) | 2000-10-18 | 2006-04-10 | Адзиномото Ко., Инк. | Способы получения кристаллов натеглинида |
| MXPA03003483A (es) | 2000-10-18 | 2003-07-14 | Ajinomoto Kk | Procedimiento para la preparacion de acilfenilalaninas. |
| DK1334964T3 (da) | 2000-10-24 | 2007-09-24 | Ajinomoto Kk | Fremgangsmåde til fremstilling af nateglinidkrystaller med B form |
| ATE406885T1 (de) * | 2000-10-24 | 2008-09-15 | Ajinomoto Kk | Nateglinid enthaltende präparate |
| MXPA03003686A (es) | 2000-10-24 | 2004-01-26 | Ajinomoto Kk | Preparaciones hidrofilas de farmaco que contienen nateglinida. |
| US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| KR100882156B1 (ko) * | 2003-08-08 | 2009-02-06 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
-
2001
- 2001-10-23 AT AT01976817T patent/ATE406885T1/de active
- 2001-10-23 DK DK01976817T patent/DK1334720T3/da active
- 2001-10-23 PT PT01976817T patent/PT1334720E/pt unknown
- 2001-10-23 EP EP01976817A patent/EP1334720B1/en not_active Expired - Lifetime
- 2001-10-23 ES ES01976817T patent/ES2307653T3/es not_active Expired - Lifetime
- 2001-10-23 CA CA2426263A patent/CA2426263C/en not_active Expired - Fee Related
- 2001-10-23 BR BR0114896-6A patent/BR0114896A/pt not_active IP Right Cessation
- 2001-10-23 DE DE60135674T patent/DE60135674D1/de not_active Expired - Lifetime
- 2001-10-23 JP JP2002537308A patent/JP4501054B2/ja not_active Expired - Fee Related
- 2001-10-23 CN CNB018212174A patent/CN100352432C/zh not_active Expired - Fee Related
- 2001-10-23 KR KR1020037005634A patent/KR100869039B1/ko not_active IP Right Cessation
- 2001-10-23 WO PCT/JP2001/009291 patent/WO2002034254A1/ja active IP Right Grant
- 2001-10-23 RU RU2003111950/04A patent/RU2271805C2/ru not_active IP Right Cessation
- 2001-10-23 AU AU2001295999A patent/AU2001295999A1/en not_active Abandoned
- 2001-10-23 MX MXPA03003685A patent/MXPA03003685A/es active IP Right Grant
- 2001-10-24 TW TW090126307A patent/TWI283573B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,898 patent/US7605180B2/en not_active Expired - Fee Related
-
2009
- 2009-04-16 US US12/424,958 patent/US20090203791A1/en not_active Abandoned
-
2010
- 2010-02-05 JP JP2010024276A patent/JP2010100654A/ja active Pending
-
2012
- 2012-10-01 JP JP2012219402A patent/JP5610165B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60135674D1 (de) | 2008-10-16 |
| CN100352432C (zh) | 2007-12-05 |
| MXPA03003685A (es) | 2004-01-26 |
| KR20030042027A (ko) | 2003-05-27 |
| EP1334720A4 (en) | 2004-02-04 |
| AU2001295999A1 (en) | 2002-05-06 |
| CA2426263C (en) | 2010-05-25 |
| JP5610165B2 (ja) | 2014-10-22 |
| JP2013028636A (ja) | 2013-02-07 |
| CA2426263A1 (en) | 2003-04-23 |
| US7605180B2 (en) | 2009-10-20 |
| WO2002034254A1 (fr) | 2002-05-02 |
| US20040014815A1 (en) | 2004-01-22 |
| BR0114896A (pt) | 2003-08-12 |
| PT1334720E (pt) | 2008-09-30 |
| EP1334720A1 (en) | 2003-08-13 |
| US20090203791A1 (en) | 2009-08-13 |
| DK1334720T3 (da) | 2009-01-19 |
| EP1334720B1 (en) | 2008-09-03 |
| JPWO2002034254A1 (ja) | 2004-08-26 |
| ATE406885T1 (de) | 2008-09-15 |
| TWI283573B (en) | 2007-07-11 |
| RU2271805C2 (ru) | 2006-03-20 |
| KR100869039B1 (ko) | 2008-11-17 |
| JP4501054B2 (ja) | 2010-07-14 |
| CN1482903A (zh) | 2004-03-17 |
| JP2010100654A (ja) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2307653T3 (es) | Preparaciones que contienen nateglinida. | |
| EP3984528B1 (en) | Pharmaceutical compositions comprising nilotinib | |
| ES2238994T3 (es) | Preparacion de cilostazol. | |
| JP5315056B2 (ja) | 固結抑制粒状製剤 | |
| TWI389691B (zh) | 可口服且具有活性成分快速釋出之固態醫藥劑型 | |
| ES2399810T3 (es) | Forma de dosificación farmacéutica sólida que comprende una dispersión sólida de ritonavir y lopinavir | |
| KR101590115B1 (ko) | 약학 조성물 | |
| JP5278708B2 (ja) | ナテグリニド含有親水性医薬製剤 | |
| US20060057207A1 (en) | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
| JP4740740B2 (ja) | 薬物含有粒子および該粒子を含む固形製剤 | |
| EA010110B1 (ru) | Дозированные формы азитромицина с пониженными побочными эффектами | |
| WO2009135646A2 (en) | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale | |
| CA2593432A1 (en) | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
| KR102684756B1 (ko) | 엔잘루타미드를 함유하는 경구 투여용 의약 조성물 | |
| ES2285866T3 (es) | Composiciones que comprenden cefuroxima axetil. | |
| ES2332880T3 (es) | Comprimidos de fenofibrato. | |
| WO2016139683A2 (en) | Pharmaceutical compositions of lurasidone and process for preparing the same | |
| JP4165224B2 (ja) | 発泡性組成物 | |
| Kumar et al. | Mouth Dissolving Tablets: A Modern Approach to Delivery of Drug | |
| WO2015199115A1 (ja) | 経口投与用医薬組成物 | |
| JP2813792B2 (ja) | マレイン酸イルソグラジン経口投与用製剤およびその製造法 | |
| Shah | Taste masking, formulation and evaluation of orally disintegrating tablet of anti-histaminic drug | |
| EP2609911A1 (en) | A novel process for preparing orally disintegrating flurbiprofen formulations | |
| JP2007513068A (ja) | Ｌｔｂ４−アンタゴニストを含む医薬製剤、並びにその調製方法及びその使用 | |
| PAUL | MASTER OF PHARMACY |